SCHEMBL4429210

SCHEMBL4429210

COc1ccc(CN2C(=O)[C@H](N)c3ccccc3-c3ccccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.52
ADK P55263 1/20 0.52
CASP3 P42574 2/20 0.51
CMA1 P23946 1/20 0.48
TSHR P16473 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
APAF1 O14727 1/20 0.47
GAA P10253 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
KDM4E B2RXH2 4/20 0.47
APP P05067 2/20 0.47
MAPT P10636 2/20 0.47
SNCA P37840 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
GSK3A P49840 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3173671 1.00 GSK3B (0.52) GSK3BADKCASP3CMA1TSHR
SCHEMBL4422395 1.00 GSK3B (0.52) GSK3BADKCASP3CMA1TSHR
Hydrochloric Acid SCHEMBL3854466 0.99 GSK3B (0.51) GSK3BADKCASP3CMA1TSHR
SCHEMBL15626933 0.84 CHRM5 (0.61) GSK3BADKCASP3CMA1TSHR
SCHEMBL15627197 0.83 KDM4E (0.48) GSK3BADKCASP3CMA1TSHR
SCHEMBL7754062 0.77 CMA1 (0.47) GSK3BADKCASP3CMA1TSHR
SCHEMBL5093349 0.77 RAB9A (0.39) TSHRGAAKDM4EMAPTSMN1; SMN2
SCHEMBL8560971 0.76 CCKBR (0.50) GSK3BADKCASP3CMA1TSHR
SCHEMBL8288083 0.76 GABRP (0.57) CASP3TSHRGAAAPPMAPT
SCHEMBL14338824 0.76 GABRP (0.57) CASP3TSHRGAAAPPMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1673347-B1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
EP-1711470-B1 MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE HOFFMANN LA ROCHE (CH) 2009-04-15 EP disclosed
US-7166587-B2 Carbamic acid alkyl ester derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-23 US disclosed
US-7160875-B2 Malonamide derivatives HOFFMANN-LA RACHE INC. (US) 2007-01-09 US disclosed
EP-1711470-A1 MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE F. HOFFMANN-LA ROCHE AG (CH) 2006-10-18 EP disclosed
EP-1673347-A1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS F. Hoffman-la Roche AG (CH) 2006-06-28 EP disclosed
WO-2005040126-A1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS F. HOFFMAN-LA ROCHE AG (CH) 2005-05-06 WO disclosed
US-20050075327-A1 Carbamic acid alkyl ester derivatives HOFFMAN-LA ROCHE INC. 2005-04-07 US disclosed
WO-2005023772-A1 MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE F. HOFFMANN-LA ROCHE AG (CH) 2005-03-17 WO disclosed
US-20050054633-A1 secretase inhibitors; therapy for Alzheimer's disease HOFFMANN-LA ROCHE INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075327-A1 Carbamic acid alkyl ester derivatives BCHE, CHRM1, ADCY7 GSK3B 4098/4885ADK 2198/4885CASP3 505/4885
US-20050054633-A1 secretase inhibitors; therapy for Alzheimer's disease BACE1, BACE2, APP GSK3B 55/4885ADK 1360/4885CASP3 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.